Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4920 | dialysis Wiki | 0.41 |
| drug2087 | Immunoglubulins Wiki | 0.41 |
| drug4668 | Virtual Assistant first, then Human Coach Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1412 | EHR-based Clinician Jumpstart Wiki | 0.41 |
| drug5022 | less-frequency hemodialysis Wiki | 0.41 |
| drug2734 | NO-Immunosuppressive Wiki | 0.41 |
| drug2089 | Immunosuppressive Wiki | 0.41 |
| drug1935 | Human Coach first, then Virtual Assistant Wiki | 0.41 |
| drug1238 | DWRX2003 Wiki | 0.24 |
| drug588 | Best Practice Wiki | 0.18 |
| drug4429 | Tocilizumab Wiki | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016491 | Peripheral Vascular Diseases NIH | 0.24 |
| D008103 | Liver Cirrhosis, NIH | 0.20 |
| D058729 | Peripheral Arterial Disease NIH | 0.20 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014652 | Vascular Diseases NIH | 0.20 |
| D007674 | Kidney Diseases NIH | 0.20 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.19 |
| D009362 | Neoplasm Metastasis NIH | 0.15 |
| D003324 | Coronary Artery Disease NIH | 0.14 |
| D051437 | Renal Insufficiency, NIH | 0.14 |
| D009369 | Neoplasms, NIH | 0.12 |
| D017563 | Lung Diseases, Interstitial NIH | 0.11 |
| D002908 | Chronic Disease NIH | 0.11 |
| D008175 | Lung Neoplasms NIH | 0.10 |
| D006333 | Heart Failure NIH | 0.10 |
| D020521 | Stroke NIH | 0.10 |
| D008173 | Lung Diseases, Obstructive NIH | 0.10 |
| D008171 | Lung Diseases, NIH | 0.07 |
| D007239 | Infection NIH | 0.04 |
| D003141 | Communicable Diseases NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001395 | Hepatic fibrosis HPO | 0.20 |
| HP:0000077 | Abnormality of the kidney HPO | 0.20 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.19 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0004950 | Peripheral arterial stenosis HPO | 0.15 |
| HP:0000083 | Renal insufficiency HPO | 0.14 |
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.14 |
| HP:0002664 | Neoplasm HPO | 0.12 |
| HP:0006515 | Interstitial pneumonitis HPO | 0.11 |
| HP:0100526 | Neoplasm of the lung HPO | 0.10 |
| HP:0001635 | Congestive heart failure HPO | 0.10 |
| HP:0001297 | Stroke HPO | 0.10 |
| HP:0006536 | Pulmonary obstruction HPO | 0.10 |
| HP:0002088 | Abnormal lung morphology HPO | 0.07 |
Navigate: Correlations HPO
There are 6 clinical trials
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over time, and across settings and providers. This study will examine the effect of the EHR-based intervention to improve quality of palliative care for patients over the age of 65 with chronic, life-limiting illness with a particular emphasis on Alzheimer's disease and related dementias (ADRD). The specific aims are: 1) to evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care discussion during the hospitalization. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital length of stay, costs of care during the hospitalization, and 30-day hospital readmissions; and 2) to conduct a mixed-methods evaluation of the implementation of the Jumpstart intervention, guided by the RE-AIM and CFIR frameworks for implementation science, incorporating quantitative assessments of effectiveness, implementation and maintenance and qualitative assessments of clinician perspectives on barriers and facilitators to future implementation and dissemination.
Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.
Measure: EHR documentation of Goals of Care discussions Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/ICU use: ICU admissions Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/ICU use: ICU length of stay Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/Hospital use: Hospital length of stay Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care: Hospital Readmissions 30 days Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care: ICU Readmissions 30 days Time: Assessed for the period between randomization and 30 days following randomizationDescription: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.
Measure: Intensity of care: Healthcare costs Time: 1 and 3 months after randomizationDescription: From Washington State death certificates.
Measure: All-cause mortality at 1 year (safety outcome) Time: 1 year after randomizationDescription: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.
Measure: Key Implementation Factors Time: 3 months after randomizationThis phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.
Measure: 7-day length of invasive mechanical ventilation (MV) Time: Up to 7 daysDescription: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: 30-day mortality rate Time: Up to 30-day after randomizationDescription: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of intensive care (ICU) transfer Time: Up to 2 yearsDescription: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of invasive mechanical ventilation Time: Up to 2 yearsDescription: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of tracheostomy Time: Up to 2 yearsDescription: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test
Measure: Length of ICU stay Time: Up to 2 yearsFacing the unusual situation imposed by the coronavirus disease, the aim of this study is to evaluate the risk and effects of less frequent hemodialysis on prevalent patients
Description: Time to all-cause and cardiovascular death
Measure: Mortality Time: From date of beginning of the study until the date of death assessed up to 52 weeksDescription: Time variation of the biological parameters mentioned in the title. Repeated measurements of laboratory variables will be averaged into patient quarterly means to minimize measurement variability.
Measure: Anemia, Nutrition, Adequation of dialysis, total ultrafiltration, ultrafiltration rate, Time: From date of beginning of the study assessed up to 52 weeksDescription: Time to first hospitalization of any cause
Measure: Hospitalization Time: From date of beginning of the study until the date of first hospitalization assessed up to 52 weeksDescription: Time to first endovascular or quirurgical intervention of the vascular access utilized at the start of the study
Measure: Vascular Access Time: From date of beginning of the study until the date of first intervention assessed up to 52 weeksStarting in late 2019, the world is facing a pandemic with the SARS-CoV-2 virus. Patients with end-stage kidney disease and on treatment with renal replacement therapy are high risk patients, as they are unable to maximize social distancing. We plan to gather epidemiological data using two different diagnostic approaches. We will compare a symptom-driven screening, in combination with a nasopharyngeal swab plus computed tomography (clinical approach) against serological surveillance.
Description: serology to test for IgG and IgM antibodies against SARS-CoV-2
Measure: Antibodies against SARS-CoV-2 Time: one yearTo understand the impact of COVID-19 restrictions on the wellbeing, quality of life and physical activity of people with end-stage renal disease, currently dialysing in-centre versus at home in the UK and their experience of telemedicine.
Description: Participants will be asked during a qualitative interview about the effect of COVID-19 restrictions on their; well-being, quality of life and physical activity and sedentary behaviours
Measure: Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours Time: Day 1Description: Participants will be asked during a qualitative interview about their perceptions and experiences of telemedicine
Measure: Thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the COVID-19 restrictions in the UK Time: Day 1The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports